June 30th 2025
Patients with relapsed or refractory chronic lymphocytic leukemia (R/R CLL) had similar results when they continued on ibrutinib or stopped and started ibrutinib plus venetoclax based on minimal residual disease (MRD) status.
Access to Cancer Care Alleviates Racial Disparities in CLL/SLL